Literature DB >> 22578274

Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.

Yong Hyun Park1, Kyung Don Baik, Young Ju Lee, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? Late recurrence more than five years after the initial treatment is one of the biological behaviours specific for RCC. In our study, late recurrence was observed in 8.8% of the patients. Also, patients with late recurrence had more favorable clinicopathological features and better prognosis with long cancer-specific survival after recurrence. Age and preoperative hs-CRP levels may be independent predictive factors for late recurrence of RCC.
OBJECTIVE: • To evaluate the clinicopathological features and prognosis of late recurrence of renal cell carcinoma (RCC). PATIENTS AND METHODS: • A total of 747 patients who had undergone curative surgery for RCC with follow-up of >5 years or recurrence within 5 years were included in the study. • The patients were stratified into four groups based on cancer-free intervals: no recurrence (no recurrence >5 years after surgery, n= 425), synchronous metastasis (n= 138), early recurrence (recurrence within 5 years, n= 143), and late recurrence (recurrence after 5 years, n= 41). • Multivariate analysis was performed to identify the clinicopathological factors affecting late recurrence and its clinical outcome.
RESULTS: • The subgroups were significantly different in clinicopathological variables, including age, preoperative haemoglobin, platelet count, high-sensitivity C-reactive protein (hs-CRP) levels, pT stage and nuclear grade. • In multiple logistic regression analysis, age (odds ratio [OR] 1.085, 95% confidence interval [CI] 1.012-1.163, P= 0.022), and preoperative hs-CRP levels (OR 6.211, 95% CI 1.590-24.270, P= 0.009) were independent predictive factors for late recurrence. • In patients with synchronous metastasis, early recurrence and late recurrence, 5-year cancer-specific survival rates after recurrence were 27.0%, 41.1% and 73.7%, respectively (P < 0.001). • Multivariate Cox analysis indicated that cancer-free interval, as well as body mass index, initial symptoms, Fuhrman's nuclear grade, sarcomatoid differentiation, lymphovascular invasion and metastasectomy, were independent predictive factors for cancer-related death.
CONCLUSIONS: • Late recurrence of RCC is not a rare event. • Patients with late recurrence had more favourable clinicopathological features and better prognosis with long cancer-specific survival after recurrence. • Age and preoperative hs-CRP levels may be independent predictive factors for late recurrence of RCC.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 22578274     DOI: 10.1111/j.1464-410X.2012.11246.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  29 in total

1.  [Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery].

Authors:  Q Tang; R C Lin; L Yao; Z Zhang; H Hao; C J Zhang; L Cai; X S Li; Z S He; L Q Zhou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

2.  Factors affecting the time to recurrence after radical nephrectomy for localized renal cell carcinoma.

Authors:  Hee-Seo Son; Seung Hyun Jeon; Sung-Goo Chang
Journal:  Korean J Urol       Date:  2013-11-06

3.  Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.

Authors:  Yoichi Fujii; Masaomi Ikeda; Kazuhiro Kurosawa; Mariko Tabata; Takayuki Kamigaito; Chihiro Hosoda; Toshikazu Okaneya
Journal:  Int J Clin Oncol       Date:  2014-12-02       Impact factor: 3.402

Review 4.  The prognostic significance of controlling nutritional status (CONUT) score for surgically treated renal cell cancer and upper urinary tract urothelial cancer: a systematic review and meta-analysis.

Authors:  Lei Peng; Chunyang Meng; Jinze Li; Chengyu You; Yuelin Du; Wei Xiong; Zhongyou Xia; Dehong Cao; Yunxiang Li
Journal:  Eur J Clin Nutr       Date:  2021-11-23       Impact factor: 4.884

5.  Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment.

Authors:  Yuki Kyoda; Ko Kobayashi; Megumi Hirobe; Tetsuya Shindo; Fumimasa Fukuta; Kohei Hashimoto; Toshiaki Tanaka; Akiko Tonooka; Hiroshi Kitamura; Satoshi Takahashi; Naoya Masumori; Tadashi Hasegawa; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

6.  The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma.

Authors:  Nathan Grimes; Cathal Hannan; Matthew Tyson; Ali Thwaini
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

7.  Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.

Authors:  John Kucharczyk; Kamal Mandalapu; Suma Satti; Marc R Matrana
Journal:  Ochsner J       Date:  2017

Review 8.  Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.

Authors:  Zhaowei Zhu; Zhoujun Shen; Chen Xu
Journal:  Mediators Inflamm       Date:  2012-07-02       Impact factor: 4.711

9.  Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?

Authors:  Sang Hyub Lee; Hee Seo Son; Seok Cho; Sang Jin Kim; Dae Seon Yoo; Seok Ho Kang; Sung Yul Park; Jinsung Park; Sung-Goo Chang; Seung Hyun Jeon
Journal:  Cancer Res Treat       Date:  2014-11-17       Impact factor: 4.679

10.  Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.

Authors:  Sohyun Park; Ho-Young Lee; Sangchul Lee
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.